Journal Browser

Journal Browser

Novel Research Targeting Cancer Metabolism: Development and Updates

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 2022

Special Issue Editors

Guest Editor
Urology, Andrology and Kidney Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari “Aldo Moro”, 70124 Bari, Italy
Interests: renal cell carcinoma; prostate cancer; bladder cancer; metabolomics; cancer metabolism; biomarkers

E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

Over the last decade, significant progress has been made in identifying molecular alterations driving cancer development thanks to the progressive use of high-throughput technologies. Metabolomics is the analysis of metabolic products in cells, tissues, organs, and the organism, which may be used to identify new biomarkers for cancer diagnosis and novel therapeutic targets. The release of various cytokines and growth factors, alterations in the cell membrane, and cancer and stromal cell interactions take place in the tumor microenvironment. The multi-omics approach, including the study of cancer cell metabolism, represents a powerful strategy for a better comprehension of cancer progression. This Special Issue of the International Journal of Molecular Sciences is dedicated to studies exploring the application of different approaches to understand the alterations of cancer metabolism and to identify potential novel molecular factors that may be therapeutically targeted.

Dr. Francesco Lasorsa
Dr. Giuseppe Lucarelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer metabolism
  • metabolomics
  • Warburg effect
  • targeted therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


16 pages, 942 KiB  
Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review
by María Antonia Pérez-Moreno, Pablo Ciudad-Gutiérrez, Didiana Jaramillo-Ruiz, Juan Luis Reguera-Ortega, Laila Abdel-kader Martín and Sandra Flores-Moreno
Int. J. Mol. Sci. 2023, 24(19), 14780; https://doi.org/10.3390/ijms241914780 - 30 Sep 2023
Viewed by 1675
The aim of this paper was to review the available evidence on the efficacy and safety of combined or sequential use of PD-1/PD-L1 immune checkpoint inhibitors (ICI) and CAR-T cell therapies in relapsed/refractory (R/R) haematological malignancies. A systematic literature review was performed until [...] Read more.
The aim of this paper was to review the available evidence on the efficacy and safety of combined or sequential use of PD-1/PD-L1 immune checkpoint inhibitors (ICI) and CAR-T cell therapies in relapsed/refractory (R/R) haematological malignancies. A systematic literature review was performed until 21 November 2022. Inclusion criteria: cohort studies/clinical trials aimed at evaluating the efficacy and/or safety of the combination of CAR-T cell therapy with PD-1/PD-L1 inhibitors in R/R haematological malignancies, which had reported results. Those focusing only on ICI or CAR-T separately or evaluating the combination in other non-hematological solid tumours were excluded. We used a specific checklist for quality assessment of the studies, and then we extracted data on efficacy or efficiency and safety. A total of 1867 articles were identified, and 9 articles were finally included (early phase studies, with small samples of patients and acceptable quality). The main pathologies were B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin’s lymphoma (B-NHL). The most studied combination was tisagenlecleucel with pembrolizumab. In terms of efficacy, there is great variability: the combination could be a promising option in B-ALL, with modest data, and in B-NHL, although hopeful responses were received, the combination does not appear better than CAR-T cell monotherapy. The safety profile could be considered comparable to that described for CAR-T cell monotherapy. Full article
(This article belongs to the Special Issue Novel Research Targeting Cancer Metabolism: Development and Updates)
Show Figures

Figure 1

Back to TopTop